Proteolysis-targeting chimeras (PROTACs) in cancer therapy
X Li, W Pu, Q Zheng, M Ai, S Chen, Y Peng - Molecular cancer, 2022 - Springer
Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …
Proteolysis targeting chimeras (PROTACs) in cancer therapy
A Ocaña, A Pandiella - Journal of Experimental & Clinical Cancer …, 2020 - Springer
Exploitation of the protein degradation machinery as a therapeutic strategy to degrade
oncogenic proteins is experiencing revolutionary advances with the development of …
oncogenic proteins is experiencing revolutionary advances with the development of …
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …
PROTAC: A promising technology for cancer treatment
X Zhou, R Dong, JY Zhang, X Zheng, LP Sun - European journal of …, 2020 - Elsevier
Proteolysis-targeting chimeric molecules (PROTACs), which attract much more attention
today, may be a potential way to treat cancer. PROTACs are made up of ligands of target …
today, may be a potential way to treat cancer. PROTACs are made up of ligands of target …
Advancing strategies for proteolysis-targeting chimera design
M Li, Y Zhi, B Liu, Q Yao - Journal of medicinal chemistry, 2023 - ACS Publications
Proteolysis-targeting chimeras (PROTACs) have shown great therapeutic potential by
degrading various disease-causing proteins, particularly those related to tumors. Therefore …
degrading various disease-causing proteins, particularly those related to tumors. Therefore …
[HTML][HTML] Current strategies for the design of PROTAC linkers: a critical review
RI Troup, C Fallan, MGJ Baud - Exploration of Targeted Anti-tumor …, 2020 - ncbi.nlm.nih.gov
Abstract PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules
consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to …
consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” to …
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …
durability of their effectiveness can be limited. Resistance to these therapies is often related …
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
H Pei, Y Peng, Q Zhao, Y Chen - RSC advances, 2019 - pubs.rsc.org
Curing malignant carcinomas is a grand ambition in the development of human health. Over
the past decades, targeted therapies have become one of the most successful ways of …
the past decades, targeted therapies have become one of the most successful ways of …
[HTML][HTML] Recent advances in PROTACs for drug targeted protein research
Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
J Gao, L Yang, S Lei, F Zhou, H Nie, B Peng, T Xu… - Science bulletin, 2023 - Elsevier
The proteolysis targeting chimeras (PROTACs) approach has attracted extensive attention in
the past decade, which represents an emerging therapeutic modality with the potential to …
the past decade, which represents an emerging therapeutic modality with the potential to …